Organization
University of Oxford, Oxford, United Kingdom
7 abstracts
Abstract
A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.Org: Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, Cardiff University, School of Medicine, Cardiff, United Kingdom, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, United Kingdom,
Abstract
Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial.Org: Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, Department of Oncology, University of Oxford, Oxford, United Kingdom, Division of Pathology and Data Analytics, University of Leeds, Leeds, United Kingdom, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom, Queen's University Belfast, Belfast, United Kingdom,
Abstract
“EVOLVING THE MANAGEMENT OF RA” PROGRAMME: EDUCATIONAL TOOLS TO SUPPORT DAILY PRACTICEOrg: LUMC, Leiden, Netherlands, Kantonsspital St. Gallen, St. Gallen, Switzerland, Medizinische Universität Wien, Vienna, Austria, University of Debrecen, Debrecen, Hungary, University of Oxford, Oxford, United Kingdom,
Abstract
ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND DISEASE ACTIVITY IN BIMEKIZUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITISOrg: Sorbonne Université and Pitié Salpétriere Hospital, Paris, France, Swedish Medical Center and University of Washington, Seattle, United States of America, Icahn School of Medicine at Mount Sinai, New York, United States of America, Hospital of the University of Pennsylvania, Philadelphia, United States of America, UCB Pharma, Slough, United Kingdom,
Abstract
APREMILAST TREATMENT IN EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS (PSA) IMPROVES CLINICAL AND PATIENT-REPORTED OUTCOMES FOR UP TO 48 WEEKS - DATA FROM THE FOREMOST STUDYOrg: Sorbonne Université and Pitié-Salpêtrière Hospital, Paris, France, University of Oxford, Oxford, United Kingdom, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Canada, University of Pennsylvania Hospital, Pennsylvania, United States of America, Aurora Health Care, Wisconsin, United States of America,
Abstract
BASELINE PAIN SEVERITY AS A PREDICTOR OF PAIN IMPROVEMENT FOLLOWING TREATMENT WITH TOFACITINIB IN PSORIATIC ARTHRITISOrg: Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States of america, UZ Leuven, Leuven, Belgium, Pfizer Inc, Groton, CT, United States of America, Swedish Medical Center and University of Washington, Seattle, WA, United States of america, Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, United States of america,